Synopsis: Specialty chemical stock in focus as it has become the first company globally to commercialise ETFA using continuous flow chemistry. The breakthrough targets a $500–600 million global market and strengthens the company’s position in fluorinated specialty chemicals and advanced manufacturing.
The shares of this company are engaged in the manufacturing of specialty chemicals, which are sold locally as well as exported to other countries are in the spotlight after the successful commercialisation of ETFA (Ethyl Trifluoroacetate)
With a market capitalisation of Rs. 14,092 cr, the shares of Anupam Rasayan India Ltd were trading at Rs. 1237.85 per share, down from its previous close of Rs. 1,256.60 per share. The stock has gained 12% over the past year, but remains under pressure in the near term, declining 7% year-to-date and 9% over the last month.
What’s the News
Anupam Rasayan India Ltd has announced the successful commercialisation of ETFA (Ethyl Trifluoroacetate) through its proprietary continuous flow chemistry platform. With this achievement, the company claims to have become the first company in the world to manufacture ETFA at a commercial scale using flow technology. The product was officially launched on June 11, 2026, marking a significant milestone in the company’s innovation and technology-driven growth journey.
Importance of ETFA in Specialty Chemicals
ETFA is a critical fluorinated chemical intermediate used in the synthesis of a wide range of organic fluorine compounds. These compounds are extensively utilized in industries such as pharmaceuticals, life sciences, agrochemicals, and advanced performance materials.
Fluorine chemistry is particularly valued for improving the stability, efficacy, and performance of end products, making ETFA an important component in the specialty chemicals value chain.
Large Global Market Opportunity
The company estimates the global addressable market for ETFA at approximately USD 500–600 million. Anupam Rasayan intends to supply the product to both domestic and international customers, including markets such as the United States, Japan, and other countries. The commercialisation of ETFA is expected to strengthen the company’s presence in the global fluorochemicals segment and create new growth opportunities.
Benefits of Continuous Flow Technology
According to the company, producing ETFA through continuous flow chemistry offers several advantages over conventional batch manufacturing processes. These include enhanced process safety, superior product consistency, improved scalability, higher operational efficiency, and a lower environmental footprint. The achievement highlights Anupam Rasayan’s expertise in developing advanced manufacturing technologies for complex fluorination chemistry.
Commenting on the development, Managing Director Anand Desai stated that the successful commercialisation of ETFA demonstrates the company’s technological capabilities and commitment to innovation. He emphasized that Anupam Rasayan will continue investing in research, advanced process technologies, and sustainable manufacturing practices.
The breakthrough further strengthens the company’s position as a leading custom synthesis and specialty chemicals manufacturer serving global customers across life sciences and performance materials sectors.
Anupam Rasayan India Ltd is one of the leading Indian specialty chemicals manufacturers focused on custom synthesis and specialty chemical production. The company operates across two key segments including Life Sciences, which includes agrochemicals, personal care, and pharmaceutical ingredients, and Performance Materials, covering electronics chemicals, EV chemicals, and polymers.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
